The application of QCT in the prognostic assessment of mCRC undergoing first-line treatment based on bevacizumab.

BACKGROUND

Bevacizumab induces muscle atrophy by changing the gene expression level of muscle tissue. Quantitative computed tomography (QCT) enables precise measurement of various body compositions, including muscle area.

MATERIALS &

METHODS

A total of 102 patients with metastatic colorectal cancer (mCRC) undergoing first-line chemotherapy based on bevacizumab were enrolled at thirst Affiliated Hospital of the University of Science and Technology of China. Their body compositions were measured respectively 1 month before and 1 month after the treatment.

RESULTS

Treatment-related decline in skeletal muscle index and visceral fat infiltration significantly affect patient prognosis.

CONCLUSION

A predictive model constructed by integrating changes in body composition with patient clinical characteristics effectively predicts the 9-month progression-free survival (PFS) of patients with mCRC.